Alpha Teknova Set to Prosper from Expected Boom in Cell & Gene Therapies: KeyBanc Analyst
Portfolio Pulse from Vandana Singh
KeyBanc Capital Markets has initiated coverage on Alpha Teknova Inc (NASDAQ:TKNO) with a Sector Weight rating. The company is a key player in the reagents and consumables needed for cell therapy production, synthetic biology, and other processes. KeyBanc notes that if Cell & Gene Therapies achieve their potential success, Alpha Teknova will be a significant research technology provider. The company is raising capital through an at-the-market program, and the analyst estimates that about $10-$20 million of capital is needed.
July 12, 2023 | 6:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alpha Teknova Inc (NASDAQ:TKNO) is expected to benefit from the potential success of Cell & Gene Therapies. The company is raising capital through an at-the-market program, and the analyst estimates that about $10-$20 million of capital is needed.
The company's focus on reagents and consumables needed for cell therapy production and synthetic biology positions it well to benefit from the potential success of Cell & Gene Therapies. The company's capital raising efforts also indicate a proactive approach to funding its growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100